Key result
Sympathoinhibitory antihypertensive treatment targets key sympathetic overactivity driving essential hypertension.
Why the study?
Sympathetic overactivity is a key factor in essential hypertension pathophysiology, promoting blood pressure increase and related cardiovascular and metabolic complications, but its modulation by antihypertensive drugs requires detailed examination.
Population
Patients with essential hypertension
Comparison
Different antihypertensive compounds and their effects on sympathetic and baroreflex function
Design
Review article
Authors
Loading...
May support sympathoinhibition as a treatment goal in essential hypertension; leaves open optimal agent selection for trials.
Sympathetic overactivity plays a central role in the pathophysiology and complications of essential hypertension, underscoring the importance of sympathoinhibition in antihypertensive therapy.
Guido M. Grassi (2004) conducted a review in Hypertension. Antihypertensive drugs was evaluated. Sympathetic overactivity is a key pathophysiological factor in essential hypertension, highlighting the rationale for achieving effective sympathoinhibition during antihypertensive drug treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: